From: Suboptimal chemotherapy is an adverse prognostic factor in osteosarcoma
Relapse free survival | Metastasis free survival | |||
---|---|---|---|---|
Five-year | P | Five-year | P | |
Total patients | 34.4 ± 4.0 | N/A | 33.6 ± 3.9 | N/A |
Age | ||||
≤11(F), ≤12(M) | 39.8 ± 14.2 | 26.6 ± 14.4 | ||
12–14 (F), 13–15 (M) | 37.3 ± 10.0 | 35.4 ± 9.6 | ||
15–39 (F), 16–39 (M) | 33.3 ± 7.0 | 33.2 ± 6.7 | ||
≥40 | 37.5 ± 28.6 | 0.941 | 37.5 ± 28.6 | 0.952 |
Gender | ||||
Male | 32.1 ± 6.3 | 31.9 ± 5.9 | ||
Female | 41.9 ± 10.0 | 0.090 | 38.0 ± 9.7 | 0.053 |
Location | ||||
Distal Femur | 37.3 ± 7.7 | 32.4 ± 7.2 | ||
Proximal Tibia | 45.9 ± 9.9 | 41.8 ± 9.4 | ||
Proximal humerus | 25.0 ± 20.4 | 25.0 ± 20.4 | ||
Proximal fibula | 30.7 ± 17.1 | 46.0 ± 17.5 | ||
Proximal Femur | 25.0 ± 21.7 | 0 | ||
Hip/Pelvic | 0 | 0 | ||
Others | 0 | 0.454 | 57.1 ± 18.7 | 0.257 |
Pathological Fracture | ||||
Yes | 0 | 0 | ||
No | 37.1 ± 5.5 | 0.319 | 35.5 ± 5.2 | 0.386 |
Subtype | ||||
Osteoblast | 33.5 ± 5.7 | 31.9 ± 5.4 | ||
Chondroblastic | 29.3 ± 15.3 | 29.3 ± 15.3 | ||
Fibroblastic | 66.7 ± 19.2 | 83.3 ± 15.2 | ||
Others | 45.0 ± 32.2 | 0.257 | 33.8 ± 26.0 | 0.326 |
Chemotherapy | ||||
Optimal Chemotherapy | 49.0 ± 7.2 | 39.5 ± 6.7 | ||
Suboptimal Chemotherapy | 30.4 ± 6.0 | 0.009* | 24.7 ± 6.1 | 0.005* |
Local Recurrence | ||||
Yes | — | 13.7 ± 8.0 | ||
No | — | — | 40.3 ± 5.8 | 0.033* |
Distal Metastasis | ||||
Yes | 21.1 ± 6.1 | — | ||
No | 50.1 ± 7.8 | 0.001* | — | — |